IL-15 Superagonist SOT201 Immunocytokine

SOT201 is an immunocytokine fusing a proprietary IL-15 superagonist to an anti-PD-1 antibody in order to directly target T cells. This fusion allows for spatial colocalization of an IL-15 superagonist with an anti-PD-1 checkpoint inhibitor, to best enhance their synergistic modes of action and potentially improve outcomes. SOT201 is one of the first IL-15/PD-1 targeting immunocytokines. 

SOT201 entered the clinic in May 2024 with Phase 1 VICTORIA-01 clinical trial (NCT06163391).